Eterna Therapeutics Inc. (ERNA)
NASDAQ (CM) NASDAQ (CM) Primary Summary
ERNA Chart
Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split
CAMBRIDGE, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced a reverse stock split of its issued and outstanding shares of common stock, par value $0.005 per share (the “Common Stock”), at a ratio of 1-for-15, effective June 12, 2025 at 12:01 a.m. Eastern Time. The Company's Common Stock is expected to begin trading on a split-adjusted basis when the market opens on June 12, 2025, under the existing trading symbol “ERNA.”
Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025
New data finds novel cell therapy successfully converts “cold” ovarian tumors into “hot,” demonstrating potential to unlock immune response and improve outcomes New data finds novel cell therapy successfully converts “cold” ovarian tumors into “hot,” demonstrating potential to unlock immune response and improve outcomes
Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations
CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the formation of ErnexaTX2, a wholly owned subsidiary based in Texas.
Eterna Therapeutics Inc. (ERNA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Eterna Therapeutics Inc. ever had a stock split?
Eterna Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Sanjeev Luther CEO | NASDAQ (CM) Exchange | 114082209 Cusip |
| US Country | 6 Employees | - Last Dividend | 12 Jun 2025 Last Split | 19 Oct 1992 IPO Date |
Overview
Eterna Therapeutics Inc. is an innovative life science company, established in 2018 and headquartered in Cambridge, Massachusetts. Specializing in mRNA cell engineering technologies, Eterna is at the forefront of developing solutions for cell reprogramming and gene editing. Through a strategic license agreement with Factor Bioscience Limited, Eterna Therapeutics leverages cutting-edge research to pave the way for advancements in genetic therapies and biotechnology.
Products and Services
- mRNA Cell Reprogramming and Gene Editing
- NoveSlice and UltraSlice Gene-Editing Proteins
- ToRNAdo mRNA Delivery System
This core technology offered by Eterna Therapeutics revolutionizes how scientists approach genetic manipulation, enabling precise alterations in the genetic makeup of cells. It is foundational for developing treatments for genetic disorders and advancing regenerative medicine.
Eterna's proprietary gene-editing proteins, NoveSlice and UltraSlice, represent groundbreaking tools in the field of genome editing. These proteins allow for highly efficient and targeted modifications of DNA, providing a robust platform for therapeutic development and biomedical research.
The ToRNAdo mRNA Delivery System is a state-of-the-art technology developed by Eterna for the efficient delivery of mRNA therapeutics. This system ensures that mRNA can be delivered to target cells with high efficacy, a crucial aspect for the success of mRNA-based therapies.
Contact Information
